視網膜靜脈阻塞市場：依疾病類型、治療方法、最終用戶、通路和地區分類。

預計到 2026 年，視網膜靜脈阻塞市場規模將達到 29.6 億美元，到 2033 年將達到 47.1 億美元。預計從 2026 年到 2033 年，該市場將以 6.9% 的複合年成長率成長。

視網膜靜脈阻塞（RVO）是最常見的視網膜血管疾病之一，也是全球範圍內導致視力喪失的主要原因之一，尤其隨著老齡化，其發生率顯著升高。視網膜靜脈阻塞是由眼內視網膜靜脈阻塞引起的，導致血流受阻、視網膜缺血和視網膜水腫，若不及時治療，最終會導致失明。視網膜靜脈阻塞主要分為兩種亞型：中央視網膜靜脈阻塞（CRVO）和分支視網膜靜脈阻塞（BRVO），並與多種常見疾病相關，包括高血壓、糖尿病、高血脂症和青光眼。

全球人口快速老化，加上慢性疾病盛行率不斷上升，加重了視網膜靜脈阻塞的整體負擔。視網膜靜脈阻塞的治療方案主要包括抗血管內皮生長因子（VEGF）藥物、皮質類固醇、手術和雷射治療等。抗VEGF療法仍是治療視網膜靜脈阻塞相關視網膜水腫的第一線療法。持續的創新，以及長效生物製藥及其生物等效藥/生物相似藥等新藥的研發，加上尖端視網膜成像技術的進步，使得患者護理水平得到提升，治療覆蓋範圍也比預期更快地擴大。

市場動態

全球視網膜靜脈阻塞市場受糖尿病、高血壓和心血管疾病盛行率上升的驅動。此外，老年人口的成長也加劇了視網膜血管疾病的風險。光學同調斷層掃描（OCT）和螢光血管血管造影術等技術的進步使得該疾病的早期診斷成為可能，而抗VEGF藥物的廣泛應用在治療視網膜靜脈阻塞相關的黃斑部水腫方面也取得了良好的效果。

然而，視網膜靜脈阻塞市場面臨許多限制因素，包括治療費用高昂、需要反覆進行玻璃體內注射以及皮質類固醇治療可能帶來的副作用。儘管如此，長效藥物遞送系統的進步、生物相似藥的出現以及新一代視網膜治療方法的研發，將為視網膜靜脈阻塞市場帶來新的成長機會。

本報告的主要特點

• 本報告揭示了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
• 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要公司採取的競爭策略的重要見解。
• 本節根據公司概況、產品系列、主要趨勢、財務表現和策略等各種參數，對全球視網膜靜脈阻塞市場的主要公司進行介紹。
• 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、技術更新、市場擴張和行銷策略做出明智的決策。
• 《全球視網膜靜脈阻塞市場》報告面向該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過分析全球視網膜靜脈阻塞市場中使用的各種策略矩陣來促進決策。

目錄

第1章：分析目標與假設

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
• 影響分析
• 主要亮點
• 監管趨勢
• 按疾病分類的市場上市與核准情況
• PEST分析
• 波特五力分析
• 市場機遇
• 監管趨勢
• 產業趨勢

第4章 全球視網膜靜脈阻塞市場：依疾病類型分類（2021-2033 年）

• 中心性視網膜靜脈阻塞（CRVO）
• 視網膜分支靜脈阻塞（BRVO）

第5章 全球視網膜靜脈阻塞市場：依治療方法分類（2021-2033 年）

• 抗 VEGF 療法
• 皮質類固醇療法
• 雷射治療
• 其他

第6章 全球視網膜靜脈阻塞市場：依最終使用者分類（2021-2033 年）

• 醫院
• 眼科診所
• 門診手術中心（ASC）
• 其他

第7章 全球視網膜靜脈阻塞市場：依通路分類（2021-2033 年）

• 醫院藥房
• 零售藥房
• 專科藥房

第8章 全球視網膜靜脈阻塞市場：依地區分類（2021-2033 年）

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 中東
  • 波灣合作理事會（GCC）國家
  • 以色列
  • 其他中東國家
• 非洲
  • 南部非洲
  • 北非
  • 中非

第9章 競爭情勢

• Regeneron Pharmaceuticals
• F. Hoffmann-La Roche Ltd.
• Bayer AG
• AbbVie Inc.
• Biogen Inc.
• Samsung Bioepis
• Sandoz Inc.
• Biocon Biologics
• Amgen Inc.
• Alimera Sciences

第10章 分析師建議

• 機會分析
• 分析師意見
• Coherent Opportunity Map (COM)

第11章 參考文獻與分析方法

• 參考
• 分析方法
• 關於 Coherent Market Insights

Retinal Vein Occlusion Market is estimated to be valued at USD 2.96 Bn in 2026 and is expected to reach USD 4.71 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.9% from 2026 to 2033.

Retinal vein occlusion (RVO) is one of the most prevalent of all ocular retinal vascular diseases, and is one of the predominant causes of visual loss worldwide especially the age-related loss of vision. Retinal vein occlusion is caused by the occlusion of an eye's retinal veins, resulting in the disruption of circulation and subsequently leads to ischemia of retina, retinal edema, and eventually blindness if not appropriately treated. Retinal vein occlusion can be classified into two primary subtypes, central RVO (CRVO) and branch RVO (BRVO) and is linked with a number of prevalent conditions namely hypertension, diabetes, hyperlipemia, and glaucoma.

Rapid global aging population along with rising prevalence of these chronic illnesses are adding to the overall burden of retinal vein occlusion. The retinal vein occlusion treatment pipeline is driven by modalities including anti-VEGF agents, corticosteroids, surgery, and laser therapy. Anti-VEGF therapies continue to be the first choice for treating retinal edema linked with retinal vein occlusion. These ongoing innovations, together with emergence of newer drug development as long-acting biologic drugs and their bioequivalents/biosimilars, development of state-of-the-art retinal imaging techniques have resulted in higher standards for patient treatment and broadened accessibility to the therapy over the anticipated timeframe.

Market Dynamics

The global retinal vein occlusion market is driven by rising prevalence of diabetes, hypertension and cardio vascular diseases. In addition to a growing geriatric populace, this phenomenon contributed towards increasing risks of the diseases related to retinal vessels. Technology advancements such as in optic coherence tomography (OCT) and fluorescence angiography are enabling better early prognosis of the condition, whilst broad application of anti-VEGF drugs have led to successful treatment results in the retinal vein occlusion linked macular oedema.

However, a number of constraints are present in the market, such as high treatment cost, repetitive intra vitreal injection treatments and probable side-effects by corticosteroid therapies. Nevertheless, advancements in long-acting drug delivery systems, the emergence of biosimilars, and the next generation retinal therapeutics will offer new opportunities for growth in the retinal vein occlusion market.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global retinal vein occlusion market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Regeneron Pharmaceuticals, F. Hoffmann-La Roche Ltd., Bayer AG, AbbVie Inc., Biogen Inc., Samsung Bioepis, Sandoz Inc., Biocon Biologics, Amgen Inc., and Alimera Sciences
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global retinal vein occlusion market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global retinal vein occlusion market

Market Segmentation

• Disease Type Insights (Revenue, USD Bn, 2021 - 2033)
• Central Retinal Vein Occlusion (CRVO)
• Branch Retinal Vein Occlusion (BRVO)
• Treatment Type Insights (Revenue, USD Bn, 2021 - 2033)
• Anti-VEGF Therapy
• Corticosteroid Therapy
• Laser Therapy
• Others
• End User Insights (Revenue, USD Bn, 2021 - 2033)
• Hospitals
• Ophthalmology Clinics
• Ambulatory Surgical Centers (ASCs)
• Others
• Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• Regeneron Pharmaceuticals
• F. Hoffmann-La Roche Ltd.
• Bayer AG
• AbbVie Inc.
• Biogen Inc.
• Samsung Bioepis
• Sandoz Inc.
• Biocon Biologics
• Amgen Inc.
• Alimera Sciences

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Retinal Vein Occlusion Market, By Disease Type
  • Global Retinal Vein Occlusion Market, By Treatment Type
  • Global Retinal Vein Occlusion Market, By End User
  • Global Retinal Vein Occlusion Market, By Distribution Channel
  • Global Retinal Vein Occlusion Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Disease Type Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Market Opportunities
• Regulatory Scenario
• Industry Trends

4. Global Retinal Vein Occlusion Market, By Disease Type, 2021-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Central Retinal Vein Occlusion (CRVO)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Branch Retinal Vein Occlusion (BRVO)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global Retinal Vein Occlusion Market, By Treatment Type, 2021-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Anti-VEGF Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Corticosteroid Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Laser Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global Retinal Vein Occlusion Market, By End User, 2021-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Ophthalmology Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Ambulatory Surgical Centers (ASCs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

7. Global Retinal Vein Occlusion Market, By Distribution Channel, 2021-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
• Specialty Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

8. Global Retinal Vein Occlusion Market, By Region, 2021 - 2033, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Regeneron Pharmaceuticals
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• F. Hoffmann-La Roche Ltd.
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bayer AG
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie Inc.
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Biogen Inc.
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Samsung Bioepis
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sandoz Inc.
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Biocon Biologics
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen Inc.
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Alimera Sciences
  • Company Highlights
  • Disease Type Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us